VAERS Explorer
Back to explore

Report #2877691

Received Dec 12, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
52 yrs
State
—
Recovered
Unknown
Vaccinated
Dec 10, 2025
Onset
Dec 10, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2C9X3R—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Early Second Dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 52-year-old male patient who received Herpes zoster (Shingrix) (batch number C9X3R, expiry date 05-JUN-2027) for prophylaxis. Concurrent medical conditions included immunocompromised. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 10-DEC-2025, the patient received the 2nd dose of Shingrix. On 10-DEC-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Early Second Dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 10-DEC-2025 The batch number was not provided upon follow- up with the reporter.

Medical history

Medical History/Concurrent Conditions: Immunocompromised